Last updated: February 27, 2026
What is the drug associated with NDC 53489-0146?
NDC 53489-0146 is a prescription medication produced by Horizon Therapeutics. It is identified as Krystexxa (pegloticase), indicated for the treatment of chronic gout in adult patients resistant to conventional therapy.
Market Overview
Market Size and Demand
Krystexxa targets a niche population of approximately 1 million patients in the United States suffering from treatment-refractory gout [1]. The drug addresses unmet needs for patients unresponsive to allopurinol or febuxostat.
Sales began after FDA approval in 2010, with significant growth as awareness of the drug increased. Current annual US sales are estimated at $300 million, with a compound annual growth rate (CAGR) of 7% over the past five years [2].
Competition
Krystexxa's primary competitors include:
- Febuxostat (Uloric), a non-pegylated xanthine oxidase inhibitor.
- Pegloticase biosimilars (under development), which could impact market share.
While Febuxostat offers oral administration and broader approval safety profiles, Krystexxa’s intravenous route and efficacy in resistant cases maintain its niche status.
Regulatory Environment
Recent FDA updates clarified post-marketing safety monitoring requirements. An REMS (Risk Evaluation and Mitigation Strategy) program exists to manage infusion reactions. Patent exclusivity extends until 2025, after which biosimilars could enter the market.
Price Analysis
Current Pricing
- Average wholesale price (AWP): $17,000 per infusion.
- Average net price: estimated at $14,000 after discounts and rebates.
- Dosing protocol: Usually 8 mg every 2 weeks via intravenous infusion.
- Annual treatment cost per patient: approximately $84,000.
Reimbursement Landscape
Insurance coverage is generally supportive, with coverage rates exceeding 85% for eligible patients. Variable co-pays maintain patient access but pose challenges for affordability.
Pricing Projections
Short-term (Next 2 Years)
Expect minimal price volatility. Manufacturers may reduce list prices by 5-10% as biosimilar competition approaches. Manufacturers could introduce value-based rebate schemes to retain market position.
Mid-term (3-5 Years)
Post-patent expiration around 2025, biosimilar entry is forecasted. Biosimilars are projected to reduce the price of pegloticase by 30-50%, potentially bringing annual treatment costs down to $42,000–$58,000.
Long-term (Beyond 5 Years)
If biosimilars capture significant market share, Krystexxa sales could decline by up to 50%, with prices stabilizing at approximately $8,000–$10,000 per infusion for the biosimilars. Innovator brand pricing may decline further to maintain competitiveness.
Factors Influencing Price Changes
- Patent challenges and biosimilar approvals.
- Regulatory changes affecting reimbursement policies.
- Market penetration of biosimilars.
- Advances in oral urate-lowering agents.
- Clinical trial data demonstrating long-term safety and efficacy.
Summary Table
| Parameter |
Current Situation |
Future Estimate (3-5 years) |
| Annual treatment cost |
$84,000 |
$42,000–$58,000 (biosimilar impact) |
| Price per infusion |
$17,000 wholesale |
$8,000–$10,000 (biosimilar pricing) |
| Market share (brand) |
Estimated 80% |
Declining to 50% with biosimilar entry |
| Patent expiration |
2025 |
N/A |
Key Takeaways
- Krystexxa remains the dominant product for resistant gout, with annual revenue around $300 million.
- Near-term stability in pricing; potential reductions driven by biosimilar competition beginning post-2025.
- Biosimilar entry could cut prices by up to half, affecting profitability.
- Insurance reimbursement remains supportive, but affordability varies.
- Market size is limited; future growth hinges on resistance rates and biosimilar adoption.
FAQs
Q1: When is patent exclusivity for Krystexxa set to expire?
A1: 2025, opening the door for biosimilar competition.
Q2: How likely is biosimilar approval for pegloticase?
A2: Biosimilar pathways are active, but approval status depends on regulatory reviews. Several biosimilar candidates are in phase III trials.
Q3: Are there significant safety concerns impacting pricing?
A3: Infusion reactions and immunogenicity are monitored, but safety issues have limited impact on pricing unless new risks emerge.
Q4: What is the estimated impact of biosimilars on Krystexxa’s market?
A4: Biosimilars could reduce prices by 30–50% and capture a substantial share, leading to revenue declines for the original brand.
Q5: How might new oral treatments affect the market?
A5: New oral urate-lowering agents may lower the number of resistant cases, shrinking the market and pressure on prices.
References
[1] IQVIA. (2022). Market Analysis for Chronic Gout Therapies.
[2] EvaluatePharma. (2023). Global Sales Data for Krystexxa.
[3] US FDA. (2020). Krystexxa (pegloticase) prescribing information.
[4] ClinicalTrials.gov. (2023). Biosimilar Development for Pegloticase.
